A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors

This is a study of BMS-986490 as a monotherapy and in combination with bevacizumab in participants with select advanced solid tumors known to express CEACAM5.

Trial Details

NCT ID
NCT06730750
Phase
PHASE1 / PHASE2
Sponsor
Bristol-Myers Squibb
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • BMS-986490
  • Bevacizumab
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Grand Rapids, Michigan, United States|42.96336,-85.66809
  • Hackensack, New Jersey, United States|40.88593,-74.04347
  • Pittsburgh, Pennsylvania, United States|40.44062,-79.99589
  • Southport, Queensland, Australia|-27.96724,153.39796

Key Eligibility Criteria

  • Documented histologically or cytologically confirmed, advanced, unresectable/metastatic solid tumor measurable by RECIST v1.1.
  • CRC: Part 1A, Part 2A-CRC, Part 1B, and Part 2B:
  • i) Locally advanced/metastatic, recurrent, or unresectable CRC with adenocarcinoma histology and whose disease has progressed after systemic cancer…
  • NSCLC: Part 2A-NSCLC/GC, 2L+ NSCLC:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →